The seasonal timing of when infants receive the new respiratory syncytial virus (RSV) immunization is crucial for ensuring ...

For meningococcal vaccines, ACIP recommended that GSK's pentavalent vaccine (Penmenvy), designed to protect against A, B, C, ...

A year after narrowing its recommendation for who should use vaccines to defend against respiratory syncytial virus (RSV), a ...

Due to a law enacted in 2023, Medicare now covers the RSV vaccine for older adults under Part D, which typically covers prescription drugs. This means you shouldn’t incur any out-of-pocket costs.

Researchers from GlaxoSmithKline have reported that a single dose of the RSV vaccine, Arexvy (RSVPreF3 OA), provides ...

However, widespread use of the vaccine by the general public will likely not be needed.” RSV is a common respiratory virus ...

The US Advisory Committee on Immunization Practices (ACIP) has voted to recommend the use of respiratory syncytial virus (RSV) vaccines, including GSK's adjuvanted Arexvy, for use in the adult ...

Persons who have already received RSV vaccination are NOT recommended to ... apply to "healthy persons ages 16 to 23 years (routine schedule) when shared clinical decision making favors ...

At its first meeting under the new administration, the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted on recommendations for several ...

The recommendation builds on the committee’s June 2024 vote for the use of RSV vaccines for people aged 60-74 at high risk. Credit: MargJohnsonVA/Shutterstock ...